Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial
Whole-breast irradiation after breast-conserving surgery for patients with early-stage breast cancer decreases ipsilateral breast-tumour recurrence (IBTR), yielding comparable results to mastectomy. It is unknown whether accelerated partial breast irradiation (APBI) to only the tumour-bearing quadra...
Saved in:
| Published in | The Lancet (British edition) Vol. 394; no. 10215; pp. 2155 - 2164 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
14.12.2019
Elsevier B.V Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0140-6736 1474-547X 1474-547X |
| DOI | 10.1016/S0140-6736(19)32514-0 |
Cover
| Abstract | Whole-breast irradiation after breast-conserving surgery for patients with early-stage breast cancer decreases ipsilateral breast-tumour recurrence (IBTR), yielding comparable results to mastectomy. It is unknown whether accelerated partial breast irradiation (APBI) to only the tumour-bearing quadrant, which shortens treatment duration, is equally effective. In our trial, we investigated whether APBI provides equivalent local tumour control after lumpectomy compared with whole-breast irradiation.
We did this randomised, phase 3, equivalence trial (NSABP B-39/RTOG 0413) in 154 clinical centres in the USA, Canada, Ireland, and Israel. Adult women (>18 years) with early-stage (0, I, or II; no evidence of distant metastases, but up to three axillary nodes could be positive) breast cancer (tumour size ≤3 cm; including all histologies and multifocal breast cancers), who had had lumpectomy with negative (ie, no detectable cancer cells) surgical margins, were randomly assigned (1:1) using a biased-coin-based minimisation algorithm to receive either whole-breast irradiation (whole-breast irradiation group) or APBI (APBI group). Whole-breast irradiation was delivered in 25 daily fractions of 50 Gy over 5 weeks, with or without a supplemental boost to the tumour bed, and APBI was delivered as 34 Gy of brachytherapy or 38·5 Gy of external bream radiation therapy in 10 fractions, over 5 treatment days within an 8-day period. Randomisation was stratified by disease stage, menopausal status, hormone-receptor status, and intention to receive chemotherapy. Patients, investigators, and statisticians could not be masked to treatment allocation. The primary outcome of invasive and non-invasive IBTR as a first recurrence was analysed in the intention-to-treat population, excluding those patients who were lost to follow-up, with an equivalency test on the basis of a 50% margin increase in the hazard ratio (90% CI for the observed HR between 0·667 and 1·5 for equivalence) and a Cox proportional hazard model. Survival was assessed by intention to treat, and sensitivity analyses were done in the per-protocol population. This trial is registered with ClinicalTrials.gov, NCT00103181.
Between March 21, 2005, and April 16, 2013, 4216 women were enrolled. 2109 were assigned to the whole-breast irradiation group and 2107 were assigned to the APBI group. 70 patients from the whole-breast irradiation group and 14 from the APBI group withdrew consent or were lost to follow-up at this stage, so 2039 and 2093 patients respectively were available for survival analysis. Further, three and four patients respectively were lost to clinical follow-up (ie, survival status was assessed by phone but no physical examination was done), leaving 2036 patients in the whole-breast irradiation group and 2089 in the APBI group evaluable for the primary outcome. At a median follow-up of 10·2 years (IQR 7·5–11·5), 90 (4%) of 2089 women eligible for the primary outcome in the APBI group and 71 (3%) of 2036 women in the whole-breast irradiation group had an IBTR (HR 1·22, 90% CI 0·94–1·58). The 10-year cumulative incidence of IBTR was 4·6% (95% CI 3·7–5·7) in the APBI group versus 3·9% (3·1–5·0) in the whole-breast irradiation group. 44 (2%) of 2039 patients in the whole-breast irradiation group and 49 (2%) of 2093 patients in the APBI group died from recurring breast cancer. There were no treatment-related deaths. Second cancers and treatment-related toxicities were similar between the two groups. 2020 patients in the whole-breast irradiation group and 2089 in APBI group had available data on adverse events. The highest toxicity grade reported was: grade 1 in 845 (40%), grade 2 in 921 (44%), and grade 3 in 201 (10%) patients in the APBI group, compared with grade 1 in 626 (31%), grade 2 in 1193 (59%), and grade 3 in 143 (7%) in the whole-breast irradiation group.
APBI did not meet the criteria for equivalence to whole-breast irradiation in controlling IBTR for breast-conserving therapy. Our trial had broad eligibility criteria, leading to a large, heterogeneous pool of patients and sufficient power to detect treatment equivalence, but was not designed to test equivalence in patient subgroups or outcomes from different APBI techniques. For patients with early-stage breast cancer, our findings support whole-breast irradiation following lumpectomy; however, with an absolute difference of less than 1% in the 10-year cumulative incidence of IBTR, APBI might be an acceptable alternative for some women.
National Cancer Institute, US Department of Health and Human Services. |
|---|---|
| AbstractList | Whole-breast irradiation after breast-conserving surgery for patients with early-stage breast cancer decreases ipsilateral breast-tumour recurrence (IBTR), yielding comparable results to mastectomy. It is unknown whether accelerated partial breast irradiation (APBI) to only the tumour-bearing quadrant, which shortens treatment duration, is equally effective. In our trial, we investigated whether APBI provides equivalent local tumour control after lumpectomy compared with whole-breast irradiation.
We did this randomised, phase 3, equivalence trial (NSABP B-39/RTOG 0413) in 154 clinical centres in the USA, Canada, Ireland, and Israel. Adult women (>18 years) with early-stage (0, I, or II; no evidence of distant metastases, but up to three axillary nodes could be positive) breast cancer (tumour size ≤3 cm; including all histologies and multifocal breast cancers), who had had lumpectomy with negative (ie, no detectable cancer cells) surgical margins, were randomly assigned (1:1) using a biased-coin-based minimisation algorithm to receive either whole-breast irradiation (whole-breast irradiation group) or APBI (APBI group). Whole-breast irradiation was delivered in 25 daily fractions of 50 Gy over 5 weeks, with or without a supplemental boost to the tumour bed, and APBI was delivered as 34 Gy of brachytherapy or 38·5 Gy of external bream radiation therapy in 10 fractions, over 5 treatment days within an 8-day period. Randomisation was stratified by disease stage, menopausal status, hormone-receptor status, and intention to receive chemotherapy. Patients, investigators, and statisticians could not be masked to treatment allocation. The primary outcome of invasive and non-invasive IBTR as a first recurrence was analysed in the intention-to-treat population, excluding those patients who were lost to follow-up, with an equivalency test on the basis of a 50% margin increase in the hazard ratio (90% CI for the observed HR between 0·667 and 1·5 for equivalence) and a Cox proportional hazard model. Survival was assessed by intention to treat, and sensitivity analyses were done in the per-protocol population. This trial is registered with ClinicalTrials.gov, NCT00103181.
Between March 21, 2005, and April 16, 2013, 4216 women were enrolled. 2109 were assigned to the whole-breast irradiation group and 2107 were assigned to the APBI group. 70 patients from the whole-breast irradiation group and 14 from the APBI group withdrew consent or were lost to follow-up at this stage, so 2039 and 2093 patients respectively were available for survival analysis. Further, three and four patients respectively were lost to clinical follow-up (ie, survival status was assessed by phone but no physical examination was done), leaving 2036 patients in the whole-breast irradiation group and 2089 in the APBI group evaluable for the primary outcome. At a median follow-up of 10·2 years (IQR 7·5–11·5), 90 (4%) of 2089 women eligible for the primary outcome in the APBI group and 71 (3%) of 2036 women in the whole-breast irradiation group had an IBTR (HR 1·22, 90% CI 0·94–1·58). The 10-year cumulative incidence of IBTR was 4·6% (95% CI 3·7–5·7) in the APBI group versus 3·9% (3·1–5·0) in the whole-breast irradiation group. 44 (2%) of 2039 patients in the whole-breast irradiation group and 49 (2%) of 2093 patients in the APBI group died from recurring breast cancer. There were no treatment-related deaths. Second cancers and treatment-related toxicities were similar between the two groups. 2020 patients in the whole-breast irradiation group and 2089 in APBI group had available data on adverse events. The highest toxicity grade reported was: grade 1 in 845 (40%), grade 2 in 921 (44%), and grade 3 in 201 (10%) patients in the APBI group, compared with grade 1 in 626 (31%), grade 2 in 1193 (59%), and grade 3 in 143 (7%) in the whole-breast irradiation group.
APBI did not meet the criteria for equivalence to whole-breast irradiation in controlling IBTR for breast-conserving therapy. Our trial had broad eligibility criteria, leading to a large, heterogeneous pool of patients and sufficient power to detect treatment equivalence, but was not designed to test equivalence in patient subgroups or outcomes from different APBI techniques. For patients with early-stage breast cancer, our findings support whole-breast irradiation following lumpectomy; however, with an absolute difference of less than 1% in the 10-year cumulative incidence of IBTR, APBI might be an acceptable alternative for some women.
National Cancer Institute, US Department of Health and Human Services. Whole-breast irradiation after breast-conserving surgery for patients with early-stage breast cancer decreases ipsilateral breast-tumour recurrence (IBTR), yielding comparable results to mastectomy. It is unknown whether accelerated partial breast irradiation (APBI) to only the tumour-bearing quadrant, which shortens treatment duration, is equally effective. In our trial, we investigated whether APBI provides equivalent local tumour control after lumpectomy compared with whole-breast irradiation.BACKGROUNDWhole-breast irradiation after breast-conserving surgery for patients with early-stage breast cancer decreases ipsilateral breast-tumour recurrence (IBTR), yielding comparable results to mastectomy. It is unknown whether accelerated partial breast irradiation (APBI) to only the tumour-bearing quadrant, which shortens treatment duration, is equally effective. In our trial, we investigated whether APBI provides equivalent local tumour control after lumpectomy compared with whole-breast irradiation.We did this randomised, phase 3, equivalence trial (NSABP B-39/RTOG 0413) in 154 clinical centres in the USA, Canada, Ireland, and Israel. Adult women (>18 years) with early-stage (0, I, or II; no evidence of distant metastases, but up to three axillary nodes could be positive) breast cancer (tumour size ≤3 cm; including all histologies and multifocal breast cancers), who had had lumpectomy with negative (ie, no detectable cancer cells) surgical margins, were randomly assigned (1:1) using a biased-coin-based minimisation algorithm to receive either whole-breast irradiation (whole-breast irradiation group) or APBI (APBI group). Whole-breast irradiation was delivered in 25 daily fractions of 50 Gy over 5 weeks, with or without a supplemental boost to the tumour bed, and APBI was delivered as 34 Gy of brachytherapy or 38·5 Gy of external bream radiation therapy in 10 fractions, over 5 treatment days within an 8-day period. Randomisation was stratified by disease stage, menopausal status, hormone-receptor status, and intention to receive chemotherapy. Patients, investigators, and statisticians could not be masked to treatment allocation. The primary outcome of invasive and non-invasive IBTR as a first recurrence was analysed in the intention-to-treat population, excluding those patients who were lost to follow-up, with an equivalency test on the basis of a 50% margin increase in the hazard ratio (90% CI for the observed HR between 0·667 and 1·5 for equivalence) and a Cox proportional hazard model. Survival was assessed by intention to treat, and sensitivity analyses were done in the per-protocol population. This trial is registered with ClinicalTrials.gov, NCT00103181.METHODSWe did this randomised, phase 3, equivalence trial (NSABP B-39/RTOG 0413) in 154 clinical centres in the USA, Canada, Ireland, and Israel. Adult women (>18 years) with early-stage (0, I, or II; no evidence of distant metastases, but up to three axillary nodes could be positive) breast cancer (tumour size ≤3 cm; including all histologies and multifocal breast cancers), who had had lumpectomy with negative (ie, no detectable cancer cells) surgical margins, were randomly assigned (1:1) using a biased-coin-based minimisation algorithm to receive either whole-breast irradiation (whole-breast irradiation group) or APBI (APBI group). Whole-breast irradiation was delivered in 25 daily fractions of 50 Gy over 5 weeks, with or without a supplemental boost to the tumour bed, and APBI was delivered as 34 Gy of brachytherapy or 38·5 Gy of external bream radiation therapy in 10 fractions, over 5 treatment days within an 8-day period. Randomisation was stratified by disease stage, menopausal status, hormone-receptor status, and intention to receive chemotherapy. Patients, investigators, and statisticians could not be masked to treatment allocation. The primary outcome of invasive and non-invasive IBTR as a first recurrence was analysed in the intention-to-treat population, excluding those patients who were lost to follow-up, with an equivalency test on the basis of a 50% margin increase in the hazard ratio (90% CI for the observed HR between 0·667 and 1·5 for equivalence) and a Cox proportional hazard model. Survival was assessed by intention to treat, and sensitivity analyses were done in the per-protocol population. This trial is registered with ClinicalTrials.gov, NCT00103181.Between March 21, 2005, and April 16, 2013, 4216 women were enrolled. 2109 were assigned to the whole-breast irradiation group and 2107 were assigned to the APBI group. 70 patients from the whole-breast irradiation group and 14 from the APBI group withdrew consent or were lost to follow-up at this stage, so 2039 and 2093 patients respectively were available for survival analysis. Further, three and four patients respectively were lost to clinical follow-up (ie, survival status was assessed by phone but no physical examination was done), leaving 2036 patients in the whole-breast irradiation group and 2089 in the APBI group evaluable for the primary outcome. At a median follow-up of 10·2 years (IQR 7·5-11·5), 90 (4%) of 2089 women eligible for the primary outcome in the APBI group and 71 (3%) of 2036 women in the whole-breast irradiation group had an IBTR (HR 1·22, 90% CI 0·94-1·58). The 10-year cumulative incidence of IBTR was 4·6% (95% CI 3·7-5·7) in the APBI group versus 3·9% (3·1-5·0) in the whole-breast irradiation group. 44 (2%) of 2039 patients in the whole-breast irradiation group and 49 (2%) of 2093 patients in the APBI group died from recurring breast cancer. There were no treatment-related deaths. Second cancers and treatment-related toxicities were similar between the two groups. 2020 patients in the whole-breast irradiation group and 2089 in APBI group had available data on adverse events. The highest toxicity grade reported was: grade 1 in 845 (40%), grade 2 in 921 (44%), and grade 3 in 201 (10%) patients in the APBI group, compared with grade 1 in 626 (31%), grade 2 in 1193 (59%), and grade 3 in 143 (7%) in the whole-breast irradiation group.FINDINGSBetween March 21, 2005, and April 16, 2013, 4216 women were enrolled. 2109 were assigned to the whole-breast irradiation group and 2107 were assigned to the APBI group. 70 patients from the whole-breast irradiation group and 14 from the APBI group withdrew consent or were lost to follow-up at this stage, so 2039 and 2093 patients respectively were available for survival analysis. Further, three and four patients respectively were lost to clinical follow-up (ie, survival status was assessed by phone but no physical examination was done), leaving 2036 patients in the whole-breast irradiation group and 2089 in the APBI group evaluable for the primary outcome. At a median follow-up of 10·2 years (IQR 7·5-11·5), 90 (4%) of 2089 women eligible for the primary outcome in the APBI group and 71 (3%) of 2036 women in the whole-breast irradiation group had an IBTR (HR 1·22, 90% CI 0·94-1·58). The 10-year cumulative incidence of IBTR was 4·6% (95% CI 3·7-5·7) in the APBI group versus 3·9% (3·1-5·0) in the whole-breast irradiation group. 44 (2%) of 2039 patients in the whole-breast irradiation group and 49 (2%) of 2093 patients in the APBI group died from recurring breast cancer. There were no treatment-related deaths. Second cancers and treatment-related toxicities were similar between the two groups. 2020 patients in the whole-breast irradiation group and 2089 in APBI group had available data on adverse events. The highest toxicity grade reported was: grade 1 in 845 (40%), grade 2 in 921 (44%), and grade 3 in 201 (10%) patients in the APBI group, compared with grade 1 in 626 (31%), grade 2 in 1193 (59%), and grade 3 in 143 (7%) in the whole-breast irradiation group.APBI did not meet the criteria for equivalence to whole-breast irradiation in controlling IBTR for breast-conserving therapy. Our trial had broad eligibility criteria, leading to a large, heterogeneous pool of patients and sufficient power to detect treatment equivalence, but was not designed to test equivalence in patient subgroups or outcomes from different APBI techniques. For patients with early-stage breast cancer, our findings support whole-breast irradiation following lumpectomy; however, with an absolute difference of less than 1% in the 10-year cumulative incidence of IBTR, APBI might be an acceptable alternative for some women.INTERPRETATIONAPBI did not meet the criteria for equivalence to whole-breast irradiation in controlling IBTR for breast-conserving therapy. Our trial had broad eligibility criteria, leading to a large, heterogeneous pool of patients and sufficient power to detect treatment equivalence, but was not designed to test equivalence in patient subgroups or outcomes from different APBI techniques. For patients with early-stage breast cancer, our findings support whole-breast irradiation following lumpectomy; however, with an absolute difference of less than 1% in the 10-year cumulative incidence of IBTR, APBI might be an acceptable alternative for some women.National Cancer Institute, US Department of Health and Human Services.FUNDINGNational Cancer Institute, US Department of Health and Human Services. Summary Background Whole-breast irradiation after breast-conserving surgery for patients with early-stage breast cancer decreases ipsilateral breast-tumour recurrence (IBTR), yielding comparable results to mastectomy. It is unknown whether accelerated partial breast irradiation (APBI) to only the tumour-bearing quadrant, which shortens treatment duration, is equally effective. In our trial, we investigated whether APBI provides equivalent local tumour control after lumpectomy compared with whole-breast irradiation. Methods We did this randomised, phase 3, equivalence trial (NSABP B-39/RTOG 0413) in 154 clinical centres in the USA, Canada, Ireland, and Israel. Adult women (>18 years) with early-stage (0, I, or II; no evidence of distant metastases, but up to three axillary nodes could be positive) breast cancer (tumour size ≤3 cm; including all histologies and multifocal breast cancers), who had had lumpectomy with negative (ie, no detectable cancer cells) surgical margins, were randomly assigned (1:1) using a biased-coin-based minimisation algorithm to receive either whole-breast irradiation (whole-breast irradiation group) or APBI (APBI group). Whole-breast irradiation was delivered in 25 daily fractions of 50 Gy over 5 weeks, with or without a supplemental boost to the tumour bed, and APBI was delivered as 34 Gy of brachytherapy or 38·5 Gy of external bream radiation therapy in 10 fractions, over 5 treatment days within an 8-day period. Randomisation was stratified by disease stage, menopausal status, hormone-receptor status, and intention to receive chemotherapy. Patients, investigators, and statisticians could not be masked to treatment allocation. The primary outcome of invasive and non-invasive IBTR as a first recurrence was analysed in the intention-to-treat population, excluding those patients who were lost to follow-up, with an equivalency test on the basis of a 50% margin increase in the hazard ratio (90% CI for the observed HR between 0·667 and 1·5 for equivalence) and a Cox proportional hazard model. Survival was assessed by intention to treat, and sensitivity analyses were done in the per-protocol population. This trial is registered with ClinicalTrials.gov, NCT00103181. Findings Between March 21, 2005, and April 16, 2013, 4216 women were enrolled. 2109 were assigned to the whole-breast irradiation group and 2107 were assigned to the APBI group. 70 patients from the whole-breast irradiation group and 14 from the APBI group withdrew consent or were lost to follow-up at this stage, so 2039 and 2093 patients respectively were available for survival analysis. Further, three and four patients respectively were lost to clinical follow-up (ie, survival status was assessed by phone but no physical examination was done), leaving 2036 patients in the whole-breast irradiation group and 2089 in the APBI group evaluable for the primary outcome. At a median follow-up of 10·2 years (IQR 7·5–11·5), 90 (4%) of 2089 women eligible for the primary outcome in the APBI group and 71 (3%) of 2036 women in the whole-breast irradiation group had an IBTR (HR 1·22, 90% CI 0·94–1·58). The 10-year cumulative incidence of IBTR was 4·6% (95% CI 3·7–5·7) in the APBI group versus 3·9% (3·1–5·0) in the whole-breast irradiation group. 44 (2%) of 2039 patients in the whole-breast irradiation group and 49 (2%) of 2093 patients in the APBI group died from recurring breast cancer. There were no treatment-related deaths. Second cancers and treatment-related toxicities were similar between the two groups. 2020 patients in the whole-breast irradiation group and 2089 in APBI group had available data on adverse events. The highest toxicity grade reported was: grade 1 in 845 (40%), grade 2 in 921 (44%), and grade 3 in 201 (10%) patients in the APBI group, compared with grade 1 in 626 (31%), grade 2 in 1193 (59%), and grade 3 in 143 (7%) in the whole-breast irradiation group. Interpretation APBI did not meet the criteria for equivalence to whole-breast irradiation in controlling IBTR for breast-conserving therapy. Our trial had broad eligibility criteria, leading to a large, heterogeneous pool of patients and sufficient power to detect treatment equivalence, but was not designed to test equivalence in patient subgroups or outcomes from different APBI techniques. For patients with early-stage breast cancer, our findings support whole-breast irradiation following lumpectomy; however, with an absolute difference of less than 1% in the 10-year cumulative incidence of IBTR, APBI might be an acceptable alternative for some women. Funding National Cancer Institute, US Department of Health and Human Services. |
| Audience | Academic |
| Author | Mamounas, Eleftherios P Julian, Thomas B Grossheim, Linda Bryant, John L Winter, Kathryn A Petersen, Ivy A Curran, Walter J Germain, Isabelle Parda, David S Kuske, Robert R Scheier, Michael F McCormick, Beryl White, Julia R Arthur, Douglas W Vicini, Frank A Cecchini, Reena S Ganz, Patricia A Paik, Soonmyung Kuerer, Henry M Rabinovitch, Rachel A Gustafson, Gregory Hudes, Richard S Bear, Harry D Vallow, Laura A Wolmark, Norman Pierce, Lori J Costantino, Joseph P |
| Author_xml | – sequence: 1 givenname: Frank A surname: Vicini fullname: Vicini, Frank A email: frank.vicini@21co.com organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 2 givenname: Reena S surname: Cecchini fullname: Cecchini, Reena S organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 3 givenname: Julia R surname: White fullname: White, Julia R organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 4 givenname: Douglas W surname: Arthur fullname: Arthur, Douglas W organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 5 givenname: Thomas B surname: Julian fullname: Julian, Thomas B organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 6 givenname: Rachel A surname: Rabinovitch fullname: Rabinovitch, Rachel A organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 7 givenname: Robert R surname: Kuske fullname: Kuske, Robert R organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 8 givenname: Patricia A surname: Ganz fullname: Ganz, Patricia A organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 9 givenname: David S surname: Parda fullname: Parda, David S organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 10 givenname: Michael F surname: Scheier fullname: Scheier, Michael F organization: Carnegie Mellon University, Pittsburgh, PA, USA – sequence: 11 givenname: Kathryn A surname: Winter fullname: Winter, Kathryn A organization: NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, USA – sequence: 12 givenname: Soonmyung surname: Paik fullname: Paik, Soonmyung organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 13 givenname: Henry M surname: Kuerer fullname: Kuerer, Henry M organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 14 givenname: Laura A surname: Vallow fullname: Vallow, Laura A organization: Mayo Clinic Florida, Jacksonville, FL, USA – sequence: 15 givenname: Lori J surname: Pierce fullname: Pierce, Lori J organization: Southwest Oncology Group Cancer Research Network, Hope Foundation for Cancer Research, Portland, OR, USA – sequence: 16 givenname: Eleftherios P surname: Mamounas fullname: Mamounas, Eleftherios P organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 17 givenname: Beryl surname: McCormick fullname: McCormick, Beryl organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 18 givenname: Joseph P surname: Costantino fullname: Costantino, Joseph P organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 19 givenname: Harry D surname: Bear fullname: Bear, Harry D organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 20 givenname: Isabelle surname: Germain fullname: Germain, Isabelle organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 21 givenname: Gregory surname: Gustafson fullname: Gustafson, Gregory organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 22 givenname: Linda surname: Grossheim fullname: Grossheim, Linda organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 23 givenname: Ivy A surname: Petersen fullname: Petersen, Ivy A organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 24 givenname: Richard S surname: Hudes fullname: Hudes, Richard S organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 25 givenname: Walter J surname: Curran fullname: Curran, Walter J organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 26 givenname: John L surname: Bryant fullname: Bryant, John L organization: NRG Oncology, Pittsburgh, PA, USA – sequence: 27 givenname: Norman surname: Wolmark fullname: Wolmark, Norman organization: NRG Oncology, Pittsburgh, PA, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31813636$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkl2L1DAUhousuB_6E5SAICtsNWnTTKuoLItfMODFKngXTtPTbtZMMpuko_Ob_JNmdmZHHVj0qhd53rc5z8lhtmedxSx7yOgzRpl4fk4Zp7mYlOKYNU_LomI8p3eyA8YnPK_45OtedrBF9rPDEC4ppVzQ6l62X7KalaIUB9nPqbNDHtHPyNzrGfgl8RhGEwNxPQGl0KCHiB2Zg48aDGk9QohEew-dhqidJdCngs1BrpwN6BfaDiSMfsDU2DtPELxZ5iHCgDcVCqxC_4IA8WA7N9MBuxMyv4CApDwheDXqBRhMEIk-_fp-drcHE_DB5nuUfXn39vPZh3z66f3Hs9NprqqaxrwSfFIUNYqWqpJhXVLWUVa0aWQGilHFi5byKjGqVYUoay560amWCV5jzXl5lIl172jnsPwOxsiNG8moXNmXYaVWrtRK1shr-5Km4Ot1cD62M-wU2ujhd9iBln-fWH0hB7eQE9Y0vKhTwfGmwLurEUOUSUpagQGLbgyyKNNgtBZVmdDHO-ilG71NXlZUVYgqzZyoJ2tqSCKltmk5EX_EAcYQpDwVtOaNqJsqgY_-vPr2zjcvJQEv14DyLgSPvVQ6Xq8_TaLN1sz5LWaqnfSu0dtyb9Y5TPteaPQyKL16EZ32qKLsnP5nw6udBmW01QrMN1z-R_4XTl4NEw |
| CitedBy_id | crossref_primary_10_1016_j_clon_2024_08_010 crossref_primary_10_3390_cancers16020270 crossref_primary_10_1177_00031348211047499 crossref_primary_10_1007_s12094_021_02618_5 crossref_primary_10_1007_s12094_022_02821_y crossref_primary_10_1016_j_ijrobp_2021_11_026 crossref_primary_10_1007_s10549_022_06516_4 crossref_primary_10_1007_s12282_024_01624_z crossref_primary_10_7759_cureus_28223 crossref_primary_10_1016_j_clbc_2021_05_015 crossref_primary_10_3390_curroncol30010015 crossref_primary_10_3389_fonc_2021_617439 crossref_primary_10_1038_s41598_025_88600_5 crossref_primary_10_1186_s13014_024_02412_x crossref_primary_10_1001_jamaoncol_2020_7468 crossref_primary_10_1016_j_jgo_2020_07_013 crossref_primary_10_1016_j_breast_2023_03_006 crossref_primary_10_1038_s41598_025_85342_2 crossref_primary_10_1016_j_clbc_2020_11_017 crossref_primary_10_1016_j_jgo_2021_05_008 crossref_primary_10_1016_j_radonc_2023_110066 crossref_primary_10_1002_cai2_106 crossref_primary_10_1245_s10434_021_11295_1 crossref_primary_10_1007_s10549_020_06086_3 crossref_primary_10_1016_j_prro_2024_04_024 crossref_primary_10_1016_j_brachy_2020_10_011 crossref_primary_10_1016_j_clbc_2023_01_012 crossref_primary_10_1016_j_ijrobp_2022_09_062 crossref_primary_10_1016_j_radonc_2024_110217 crossref_primary_10_1136_jitc_2022_006618 crossref_primary_10_1016_j_radonc_2024_110573 crossref_primary_10_3389_fcell_2024_1431883 crossref_primary_10_1088_1361_6560_ac5ce5 crossref_primary_10_1016_j_brachy_2020_10_010 crossref_primary_10_1007_s12253_020_00821_3 crossref_primary_10_1038_s41523_023_00591_6 crossref_primary_10_3390_curroncol30010032 crossref_primary_10_1245_s10434_023_13233_9 crossref_primary_10_1097_MD_0000000000024098 crossref_primary_10_1177_11782234231224267 crossref_primary_10_1080_23808993_2021_1897463 crossref_primary_10_1016_j_brachy_2022_01_008 crossref_primary_10_1007_s12609_023_00499_x crossref_primary_10_1016_j_ctro_2023_100639 crossref_primary_10_1016_j_adro_2020_04_013 crossref_primary_10_1200_JCO_24_00600 crossref_primary_10_1016_j_ijrobp_2020_06_064 crossref_primary_10_1016_S0140_6736_19_32959_9 crossref_primary_10_1007_s00066_023_02128_z crossref_primary_10_2147_IJN_S296513 crossref_primary_10_1245_s10434_020_09432_3 crossref_primary_10_1016_j_ijrobp_2020_07_2312 crossref_primary_10_1007_s12609_021_00422_2 crossref_primary_10_1016_j_ijrobp_2021_03_052 crossref_primary_10_1016_j_prro_2024_04_019 crossref_primary_10_2217_fon_2020_0574 crossref_primary_10_1007_s12032_021_01514_w crossref_primary_10_1007_s11547_022_01563_9 crossref_primary_10_3389_fonc_2024_1424630 crossref_primary_10_1002_jmrs_590 crossref_primary_10_1016_j_ijrobp_2025_02_012 crossref_primary_10_1016_j_breast_2020_10_010 crossref_primary_10_1007_s12609_022_00447_1 crossref_primary_10_1007_s11864_024_01253_w crossref_primary_10_1016_j_brachy_2020_02_011 crossref_primary_10_1016_j_radonc_2022_03_010 crossref_primary_10_1016_j_canrad_2021_08_004 crossref_primary_10_1245_s10434_020_08450_5 crossref_primary_10_1016_j_ijrobp_2020_06_054 crossref_primary_10_1007_s12609_021_00411_5 crossref_primary_10_1016_j_ijrobp_2024_08_037 crossref_primary_10_3919_jjsa_84_238 crossref_primary_10_1002_pro6_1183 crossref_primary_10_3389_fonc_2021_713328 crossref_primary_10_1016_j_radonc_2024_110591 crossref_primary_10_1159_000541340 crossref_primary_10_1016_j_radonc_2024_110471 crossref_primary_10_1097_COC_0000000000000970 crossref_primary_10_1016_j_prro_2021_08_009 crossref_primary_10_1007_s12094_022_02823_w crossref_primary_10_1016_j_clbc_2023_12_012 crossref_primary_10_1016_j_ijrobp_2021_02_023 crossref_primary_10_1016_S1470_2045_23_00018_9 crossref_primary_10_1111_ajco_13462 crossref_primary_10_1016_S1470_2045_24_00661_2 crossref_primary_10_1016_j_brachy_2020_06_008 crossref_primary_10_1016_j_clbc_2023_10_001 crossref_primary_10_1200_JCO_20_00650 crossref_primary_10_1016_j_radonc_2022_09_024 crossref_primary_10_1007_s12609_020_00384_x crossref_primary_10_1016_S0140_6736_20_30932_6 crossref_primary_10_1200_JCO_19_02388 crossref_primary_10_1186_s13058_021_01424_9 crossref_primary_10_1177_15330338241234788 crossref_primary_10_1016_j_ijrobp_2020_09_009 crossref_primary_10_1177_17588359231161415 crossref_primary_10_1186_s13014_020_01501_x crossref_primary_10_3389_fonc_2023_1195266 crossref_primary_10_1200_OP_24_00538 crossref_primary_10_3389_fonc_2022_1048512 crossref_primary_10_1016_j_radonc_2022_10_025 crossref_primary_10_1016_j_ijrobp_2021_02_034 crossref_primary_10_1016_j_breast_2023_04_007 crossref_primary_10_1111_iwj_13350 crossref_primary_10_1016_j_brachy_2020_06_018 crossref_primary_10_1016_j_ejso_2020_05_005 crossref_primary_10_1016_j_ijrobp_2023_10_016 crossref_primary_10_1016_j_rpor_2020_05_004 crossref_primary_10_1093_jnci_djad100 crossref_primary_10_1097_COC_0000000000000966 crossref_primary_10_1016_j_radonc_2021_07_020 crossref_primary_10_1186_s13014_023_02365_7 crossref_primary_10_1097_COC_0000000000000964 crossref_primary_10_1016_j_prro_2022_01_006 crossref_primary_10_1016_j_ctro_2021_04_005 crossref_primary_10_1016_S1470_2045_21_00080_2 crossref_primary_10_1007_s00066_020_01744_3 crossref_primary_10_1016_j_brachy_2023_02_006 crossref_primary_10_1016_j_ijrobp_2021_12_161 crossref_primary_10_1007_s00432_023_04973_y crossref_primary_10_1016_j_clbc_2021_02_009 crossref_primary_10_3390_cancers15123128 crossref_primary_10_1038_s41416_020_01233_5 crossref_primary_10_1016_j_brachy_2023_01_002 crossref_primary_10_1016_j_suc_2022_08_015 crossref_primary_10_1016_j_ijrobp_2020_11_042 crossref_primary_10_1016_j_ijrobp_2022_03_007 crossref_primary_10_1016_j_prro_2022_02_001 crossref_primary_10_1016_j_prro_2024_11_007 crossref_primary_10_1016_j_ijrobp_2020_11_044 crossref_primary_10_1016_j_ijrobp_2023_05_018 crossref_primary_10_1016_j_annonc_2021_06_023 crossref_primary_10_1016_j_prro_2023_03_006 crossref_primary_10_2478_raon_2021_0016 crossref_primary_10_1016_j_brachy_2021_02_003 crossref_primary_10_1016_j_ijrobp_2020_11_041 crossref_primary_10_1200_JCO_21_01896 crossref_primary_10_1007_s12094_021_02728_0 crossref_primary_10_1016_j_canrad_2020_06_018 crossref_primary_10_3390_cancers15041138 crossref_primary_10_1016_j_adro_2022_101095 crossref_primary_10_1016_j_prro_2023_10_009 crossref_primary_10_1245_s10434_020_09526_y crossref_primary_10_1016_j_clbc_2020_09_004 crossref_primary_10_1093_jjco_hyaa064 crossref_primary_10_3390_cancers17071095 crossref_primary_10_1016_j_clbc_2024_07_010 crossref_primary_10_1016_j_ijrobp_2022_03_010 crossref_primary_10_1016_j_prro_2025_02_008 crossref_primary_10_1186_s13014_021_01752_2 crossref_primary_10_1007_s00066_020_01613_z crossref_primary_10_1016_j_brachy_2022_09_005 crossref_primary_10_1016_j_suc_2022_08_002 crossref_primary_10_1093_jnci_djae219 crossref_primary_10_1016_j_adro_2021_100701 crossref_primary_10_1038_s41523_021_00242_8 crossref_primary_10_1097_JCMA_0000000000000893 crossref_primary_10_1016_j_canrad_2022_04_003 crossref_primary_10_1021_acs_nanolett_3c00191 crossref_primary_10_1016_j_critrevonc_2020_102967 crossref_primary_10_1016_j_clbc_2020_04_003 crossref_primary_10_1016_j_ejca_2022_04_038 crossref_primary_10_1016_j_ijrobp_2022_09_083 crossref_primary_10_1016_j_soc_2023_03_002 crossref_primary_10_1097_COC_0000000000000945 crossref_primary_10_1055_a_1942_5061 crossref_primary_10_1016_j_ijrobp_2020_10_009 crossref_primary_10_3390_cancers16112122 crossref_primary_10_1016_j_clon_2023_12_002 crossref_primary_10_1016_j_ijrobp_2021_06_026 crossref_primary_10_1017_S146039692000120X crossref_primary_10_1016_j_radonc_2021_03_029 crossref_primary_10_1016_j_ijrobp_2021_01_015 crossref_primary_10_1007_s00066_020_01609_9 crossref_primary_10_1016_j_semradonc_2022_01_012 crossref_primary_10_1200_JCO_22_01751 crossref_primary_10_1016_S1470_2045_21_00539_8 crossref_primary_10_3389_fonc_2022_1049704 crossref_primary_10_3390_cancers15041260 crossref_primary_10_21294_1814_4861_2023_22_1_119_127 crossref_primary_10_1016_j_adro_2021_100731 crossref_primary_10_1002_ctm2_70036 crossref_primary_10_1200_JCO_20_01703 crossref_primary_10_1097_XCS_0000000000000869 crossref_primary_10_1200_JCO_20_01397 crossref_primary_10_37549_ARO1318 crossref_primary_10_3389_fonc_2021_649301 crossref_primary_10_1001_jamaoncol_2020_0795 crossref_primary_10_1016_j_ijrobp_2022_11_031 crossref_primary_10_3390_curroncol31030121 crossref_primary_10_1016_j_ctro_2023_100692 crossref_primary_10_1016_S0140_6736_24_00425_2 crossref_primary_10_3390_cancers14041066 crossref_primary_10_4103_jmp_jmp_146_21 crossref_primary_10_1002_14651858_CD007077_pub4 crossref_primary_10_1055_s_0044_1786517 crossref_primary_10_1093_jjco_hyaa029 crossref_primary_10_1007_s10549_023_07112_w crossref_primary_10_1245_s10434_021_09777_3 crossref_primary_10_1159_000509410 crossref_primary_10_1055_a_1826_2992 crossref_primary_10_4048_jbc_2023_0296 crossref_primary_10_1200_JCO_24_01625 crossref_primary_10_1002_onco_13980 crossref_primary_10_1007_s12094_021_02664_z crossref_primary_10_1016_j_adro_2023_101263 crossref_primary_10_1200_JCO_20_00070 crossref_primary_10_3390_cancers12082309 crossref_primary_10_1002_acm2_14363 crossref_primary_10_1186_s40792_022_01546_y crossref_primary_10_3389_fonc_2021_645615 crossref_primary_10_3389_fonc_2020_01445 crossref_primary_10_1016_j_brachy_2022_07_004 crossref_primary_10_1016_j_ctro_2022_11_013 crossref_primary_10_3390_curroncol28050335 crossref_primary_10_1007_s12282_024_01568_4 crossref_primary_10_1016_j_brachy_2021_01_002 crossref_primary_10_1159_000506254 crossref_primary_10_1016_j_brachy_2021_10_003 crossref_primary_10_1186_s13014_023_02299_0 crossref_primary_10_3390_cancers13122967 crossref_primary_10_1007_s12282_024_01546_w crossref_primary_10_1007_s12094_021_02636_3 crossref_primary_10_3390_cancers15174343 crossref_primary_10_1136_bmj_m2836 crossref_primary_10_3390_cancers14102564 crossref_primary_10_1016_j_cellsig_2024_111262 crossref_primary_10_1016_j_prro_2023_11_001 crossref_primary_10_1200_OP_21_00635 crossref_primary_10_3390_curroncol28050341 crossref_primary_10_1200_JCO_22_00451 crossref_primary_10_1016_j_amjsurg_2023_03_004 crossref_primary_10_3390_healthcare12070795 crossref_primary_10_1016_j_clinimag_2021_06_035 crossref_primary_10_1007_s12094_024_03405_8 crossref_primary_10_1016_j_adro_2020_10_018 crossref_primary_10_1016_j_clon_2022_03_001 crossref_primary_10_1016_j_radonc_2024_110515 crossref_primary_10_1016_j_ejso_2021_10_030 crossref_primary_10_1016_j_brachy_2021_08_007 crossref_primary_10_1016_j_ctro_2020_03_009 crossref_primary_10_1016_j_ijrobp_2023_08_022 crossref_primary_10_1016_S1470_2045_23_00062_1 crossref_primary_10_4274_ejbh_galenos_2024_2024_3_14 crossref_primary_10_1016_j_ijrobp_2023_12_026 crossref_primary_10_1016_j_clon_2023_05_013 crossref_primary_10_1016_j_breast_2024_103796 crossref_primary_10_3390_biomedicines11010098 crossref_primary_10_1016_j_radonc_2024_110193 crossref_primary_10_1016_j_radonc_2024_110195 crossref_primary_10_1016_j_adro_2021_100752 crossref_primary_10_1016_j_ijrobp_2020_11_006 crossref_primary_10_1016_j_radonc_2021_09_023 crossref_primary_10_7759_cureus_37932 crossref_primary_10_1016_j_ijrobp_2024_10_024 crossref_primary_10_1016_j_canrad_2021_09_011 crossref_primary_10_1016_j_brachy_2020_08_012 crossref_primary_10_1016_j_ijrobp_2024_10_029 crossref_primary_10_1016_j_ctro_2022_08_013 crossref_primary_10_1016_j_jaccao_2021_06_007 crossref_primary_10_1001_jamanetworkopen_2021_3304 crossref_primary_10_1016_j_ijrobp_2020_02_021 crossref_primary_10_1016_j_brachy_2022_06_002 crossref_primary_10_1007_s10549_023_07190_w crossref_primary_10_1016_j_clbc_2020_12_007 crossref_primary_10_1007_s12282_025_01674_x crossref_primary_10_1016_j_eswa_2023_122209 crossref_primary_10_1016_j_ijrobp_2022_12_036 crossref_primary_10_1016_j_radonc_2024_110543 crossref_primary_10_3390_cancers15010298 crossref_primary_10_1016_j_adro_2022_101111 crossref_primary_10_1002_cncr_33422 crossref_primary_10_1016_S1283_081X_21_45718_8 crossref_primary_10_1200_JCO_22_01485 crossref_primary_10_1016_j_adro_2023_101233 crossref_primary_10_1002_acm2_13506 crossref_primary_10_1177_03008916241291305 crossref_primary_10_2217_bmm_2020_0683 crossref_primary_10_1002_mp_15651 crossref_primary_10_1016_j_apjon_2024_100602 crossref_primary_10_1016_j_ijrobp_2021_10_014 crossref_primary_10_1016_j_brachy_2022_12_009 crossref_primary_10_3390_jpm11040289 crossref_primary_10_6004_jnccn_2022_0030 crossref_primary_10_1016_j_ijbiomac_2024_138930 crossref_primary_10_1016_j_ijrobp_2022_12_028 crossref_primary_10_1200_JCO_20_01243 crossref_primary_10_3389_fonc_2023_1117874 crossref_primary_10_1016_j_senol_2023_100500 crossref_primary_10_1007_s10549_021_06206_7 crossref_primary_10_1016_j_ijrobp_2024_09_019 crossref_primary_10_1186_s12885_023_10910_6 crossref_primary_10_1007_s12282_020_01114_y crossref_primary_10_1016_j_senol_2023_100504 crossref_primary_10_3390_curroncol29070369 crossref_primary_10_1016_j_soc_2023_05_008 crossref_primary_10_1055_a_1103_3066 crossref_primary_10_3389_fonc_2020_550950 crossref_primary_10_1056_NEJMcpc2002422 crossref_primary_10_1016_j_ijrobp_2020_12_007 crossref_primary_10_1007_s12609_023_00497_z crossref_primary_10_3389_fonc_2023_1146754 crossref_primary_10_1016_j_radonc_2021_09_006 crossref_primary_10_1016_j_prro_2023_12_015 crossref_primary_10_1016_j_radonc_2021_11_019 crossref_primary_10_1245_s10434_023_14448_6 crossref_primary_10_1186_s13058_022_01582_4 crossref_primary_10_1016_j_yasu_2024_04_005 crossref_primary_10_1007_s00066_021_01808_y crossref_primary_10_1016_j_canrad_2021_11_013 crossref_primary_10_1007_s12609_020_00401_z crossref_primary_10_1016_j_adro_2023_101334 crossref_primary_10_1016_j_ijrobp_2024_07_2326 crossref_primary_10_1007_s10549_020_05706_2 crossref_primary_10_1016_j_adro_2020_03_011 crossref_primary_10_1016_j_breast_2025_104459 crossref_primary_10_1016_j_ijrobp_2023_07_032 crossref_primary_10_1016_j_yao_2021_02_003 crossref_primary_10_1016_j_ijrobp_2023_07_018 crossref_primary_10_1038_s41571_019_0323_0 crossref_primary_10_1016_j_phro_2024_100659 crossref_primary_10_1007_s12282_023_01513_x crossref_primary_10_1245_s10434_020_09447_w crossref_primary_10_1016_j_brachy_2022_02_002 crossref_primary_10_1016_j_ijrobp_2023_08_062 crossref_primary_10_1007_s12609_024_00565_y crossref_primary_10_1016_j_adro_2023_101324 crossref_primary_10_1016_j_brachy_2020_03_003 crossref_primary_10_1016_j_breast_2024_103759 crossref_primary_10_1016_j_ctrv_2022_102375 |
| Cites_doi | 10.1056/NEJMoa022152 10.1093/jnci/93.17.1344 10.1200/JCO.2012.45.2615 10.1158/1538-7445.SABCS18-GS4-04 10.1016/S1470-2045(14)71221-5 10.1007/s13187-016-1016-3 10.1007/s10549-018-4881-0 10.1093/jnci/djt340 10.1016/S0140-6736(05)67887-7 10.1158/1538-7445.SABCS18-GS4-03 10.1016/S0140-6736(15)00471-7 10.1016/S0140-6736(17)31145-5 10.1016/S0140-6736(11)61629-2 10.1016/S1470-2045(16)30067-5 10.1016/j.clon.2015.04.034 10.1001/jama.1991.03460030097037 10.1016/j.breast.2013.12.009 10.1038/bjc.1978.124 10.1016/j.ejca.2014.12.013 10.1016/j.ijrobp.2010.11.077 10.1016/j.prro.2016.09.007 |
| ContentType | Journal Article |
| Copyright | 2019 Elsevier Ltd Copyright © 2019 Elsevier Ltd. All rights reserved. COPYRIGHT 2019 Elsevier B.V. 2019. Elsevier Ltd |
| Copyright_xml | – notice: 2019 Elsevier Ltd – notice: Copyright © 2019 Elsevier Ltd. All rights reserved. – notice: COPYRIGHT 2019 Elsevier B.V. – notice: 2019. Elsevier Ltd |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7X8 5PM ADTOC UNPAY |
| DOI | 10.1016/S0140-6736(19)32514-0 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts ProQuest Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection ProQuest Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland British Nursing Database British Nursing Index ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central British Nursing Index (BNI) (1985 to Present) Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection (via ProQuest) British Nursing Index Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Psychology Database Research Library Science Database (via ProQuest SciTech Premium Collection) Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology [Accès UNIL ; CHUV ; HEP Vaud ; Sites BCUL] ProQuest Central Basic SIRS Editorial MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest One Psychology MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 4 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-547X |
| EndPage | 2164 |
| ExternalDocumentID | oai:pubmedcentral.nih.gov:7199428 PMC7199428 A608496895 31813636 10_1016_S0140_6736_19_32514_0 S0140673619325140 |
| Genre | Clinical Trial, Phase III Multicenter Study Equivalence Trial Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | Michigan United States--US |
| GeographicLocations_xml | – name: Michigan – name: United States--US |
| GrantInformation | National Cancer Institute, US Department of Health and Human Services. |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: U10 CA180868 – fundername: NCI NIH HHS grantid: P30 CA016058 – fundername: NCI NIH HHS grantid: U10 CA180822 – fundername: NCI NIH HHS grantid: U24-CA-19067 – fundername: NCI NIH HHS grantid: UG1 CA189867 – fundername: NCI NIH HHS grantid: UG1 CA233331 – fundername: NCI NIH HHS grantid: UG1 CA233324 – fundername: NCI NIH HHS grantid: R03 CA099508 – fundername: NCI NIH HHS grantid: P30 CA008748 |
| GroupedDBID | --- --K --M .1- .55 .CO .FO 0R~ 123 1B1 1P~ 1RT 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUFD ABUWG ACGFS ACGOD ACIEU ACIUM ACLOT ACPRK ACRLP ACVFH ADBBV ADCNI AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGHFR AHMBA AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EFKBS EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UV1 WOW X7M XAX XDU YYM Z5R ZMT ~HD 04C 88A AACTN ABLVK ABYKQ AFKWA AJOXV AMFUW M0L M41 RIG SDF XFK ZA5 .GJ 3EH 3O- 41~ 8WZ A6W AAEJM AAKAS AAQXK AAYXX ABDBF ABWVN ACRPL ACUHS ADMUD ADNMO ADXHL ADZCM AFFNX AGQPQ AHHHB AHQJS AIGII AJJEV AKVCP ARTTT ASPBG AVWKF AZFZN CITATION D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EJD EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H MVM OVD PUEGO Q~Q R2- SV3 TEORI TH9 UHU UQL WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 AFCTW ALIPV CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM ADTOC UNPAY |
| ID | FETCH-LOGICAL-c580t-5647228e6b0c31e8301d012b8131ac10c42b045722cbc263846f6dcb1648e8443 |
| IEDL.DBID | UNPAY |
| ISSN | 0140-6736 1474-547X |
| IngestDate | Sun Oct 26 04:13:20 EDT 2025 Tue Sep 30 16:57:56 EDT 2025 Sun Sep 28 03:50:28 EDT 2025 Tue Oct 07 07:17:03 EDT 2025 Thu Oct 16 16:04:05 EDT 2025 Wed Feb 19 02:26:13 EST 2025 Thu Oct 02 04:26:08 EDT 2025 Thu Apr 24 22:54:50 EDT 2025 Fri Feb 23 02:40:57 EST 2024 Tue Oct 14 19:29:46 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10215 |
| Language | English |
| License | Copyright © 2019 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c580t-5647228e6b0c31e8301d012b8131ac10c42b045722cbc263846f6dcb1648e8443 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Prof Bryant died in June, 2019 Correspondence to: Prof Frank A Vicini, 21st Century Oncology, Michigan Healthcare Professionals, Pontiac, MI 48341, USA frank.vicini@21co.com All authors contributed to: the conception or design of the work, or the acquisition, analysis, or interpretation of data; drafting the work or revising it critically for important intellectual content; final approval of the version to be published; and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any parts are appropriately investigated and resolved. FAV was responsible for the literature search and figures. JRW oversaw the trial and performed the radiation quality assurance review. WJC Jr contributed to protocol review and securing funding. JLB participated in form review. TBJ contributed to daily trial monitoring. BMcC contributed to pilot studies of accelerated partial breast irradiation. Contributors |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://www.ncbi.nlm.nih.gov/pmc/articles/7199428 |
| PMID | 31813636 |
| PQID | 2325265012 |
| PQPubID | 40246 |
| PageCount | 10 |
| ParticipantIDs | unpaywall_primary_10_1016_s0140_6736_19_32514_0 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7199428 proquest_miscellaneous_2322808653 proquest_journals_2325265012 gale_incontextgauss__A608496895 pubmed_primary_31813636 crossref_citationtrail_10_1016_S0140_6736_19_32514_0 crossref_primary_10_1016_S0140_6736_19_32514_0 elsevier_sciencedirect_doi_10_1016_S0140_6736_19_32514_0 elsevier_clinicalkey_doi_10_1016_S0140_6736_19_32514_0 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-12-14 |
| PublicationDateYYYYMMDD | 2019-12-14 |
| PublicationDate_xml | – month: 12 year: 2019 text: 2019-12-14 day: 14 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2019 |
| Publisher | Elsevier Ltd Elsevier B.V Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier B.V – name: Elsevier Limited |
| References | Hoopes, Kaziksa, Chapin (bib7) 2012; 82 Livi, Meattini, Marrazzo (bib21) 2015; 51 White, Freedman (bib14) 1978; 37 Clarke, Collins, Darby (bib2) 2005; 366 Kunkler, Williams, Jack (bib11) 2015; 16 Parekh, Fu, Hu (bib5) 2018; 172 Strnad, Ott, Hildebrandt (bib20) 2016; 387 Coles, Griffin, Kirby (bib22) 2017; 390 Nattinger, Kneusel, Hoffmann, Gilligan (bib3) 2001; 93 Bonin, McGuffin, Presutti (bib8) 2018; 33 Rippy, Anisworth, Sathananthan (bib9) 2014; 23 Whelan T, Julian J, Levine M, et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiation therapy (3D-CRT). San Antonio Breast Cancer Symposium; San Antonio, TX: Dec 4–8, 2018 (abstr GS4–03). Correa, Harris, Leonardi (bib15) 2017; 7 (bib16) 1991; 265 Vicini FA, Cecchini RS, White JR, et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 4–8, 2018 (abstr GS4-04). Fisher, Anderson, Bryant (bib1) 2002; 347 Pan, Smith, Shih (bib4) 2014; 106 DeSantis, Ma, Goding Sauer, Newman, Jemal (bib18) 2017; 67 (bib12) 2011; 378 Hughes, Schnaper, Bellon (bib10) 2013; 31 van Maaren, de Munck, de Bock (bib17) 2016; 17 Fisher, Anderson, Redmond, Fisher (bib13) 1992; 8 Lam, Cook, Foster (bib6) 2015; 27 Bonin (10.1016/S0140-6736(19)32514-0_bib8) 2018; 33 Fisher (10.1016/S0140-6736(19)32514-0_bib13) 1992; 8 10.1016/S0140-6736(19)32514-0_bib19 DeSantis (10.1016/S0140-6736(19)32514-0_bib18) 2017; 67 Coles (10.1016/S0140-6736(19)32514-0_bib22) 2017; 390 Lam (10.1016/S0140-6736(19)32514-0_bib6) 2015; 27 Correa (10.1016/S0140-6736(19)32514-0_bib15) 2017; 7 White (10.1016/S0140-6736(19)32514-0_bib14) 1978; 37 Parekh (10.1016/S0140-6736(19)32514-0_bib5) 2018; 172 Strnad (10.1016/S0140-6736(19)32514-0_bib20) 2016; 387 Clarke (10.1016/S0140-6736(19)32514-0_bib2) 2005; 366 Livi (10.1016/S0140-6736(19)32514-0_bib21) 2015; 51 10.1016/S0140-6736(19)32514-0_bib23 Fisher (10.1016/S0140-6736(19)32514-0_bib1) 2002; 347 (10.1016/S0140-6736(19)32514-0_bib12) 2011; 378 Hoopes (10.1016/S0140-6736(19)32514-0_bib7) 2012; 82 Rippy (10.1016/S0140-6736(19)32514-0_bib9) 2014; 23 Hughes (10.1016/S0140-6736(19)32514-0_bib10) 2013; 31 Kunkler (10.1016/S0140-6736(19)32514-0_bib11) 2015; 16 van Maaren (10.1016/S0140-6736(19)32514-0_bib17) 2016; 17 (10.1016/S0140-6736(19)32514-0_bib16) 1991; 265 Pan (10.1016/S0140-6736(19)32514-0_bib4) 2014; 106 Nattinger (10.1016/S0140-6736(19)32514-0_bib3) 2001; 93 31900442 - Nat Rev Clin Oncol. 2020 Mar;17(3):134 31813634 - Lancet. 2019 Dec 14;394(10215):2127-2129 33220220 - Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1123-1128 |
| References_xml | – volume: 378 start-page: 1707 year: 2011 end-page: 1716 ident: bib12 article-title: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials publication-title: Lancet – volume: 106 year: 2014 ident: bib4 article-title: Factors contributing to underuse of radiation among younger women with breast cancer publication-title: J Natl Cancer Inst – volume: 16 start-page: 266 year: 2015 end-page: 273 ident: bib11 article-title: Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial publication-title: Lancet Oncol – volume: 366 start-page: 2087 year: 2005 end-page: 2106 ident: bib2 article-title: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials publication-title: Lancet – reference: Vicini FA, Cecchini RS, White JR, et al. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 4–8, 2018 (abstr GS4-04). – volume: 8 start-page: 161 year: 1992 end-page: 166 ident: bib13 article-title: Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation: pathological findings from NSABP protocol B-06 publication-title: Semin Surg Oncol – volume: 23 start-page: 273 year: 2014 end-page: 278 ident: bib9 article-title: Influences on decision for mastectomy in patients eligible for breast conserving surgery publication-title: Breast – volume: 51 start-page: 451 year: 2015 end-page: 463 ident: bib21 article-title: Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial publication-title: Eur J Cancer – volume: 33 start-page: 37 year: 2018 end-page: 43 ident: bib8 article-title: Breast cancer patients' preferences for adjuvant radiotherapy: whole breast irradiation publication-title: J Canc Educ – volume: 82 start-page: 674 year: 2012 end-page: 681 ident: bib7 article-title: Patient preferences and physician practice patterns regarding breast radiotherapy publication-title: Int J Radiat Oncol Biol Phys – volume: 67 start-page: 439 year: 2017 end-page: 448 ident: bib18 article-title: Breast cancer statistics, 2017, racial disparity in mortality by state publication-title: CA Cancer J Clin – volume: 37 start-page: 849 year: 1978 end-page: 857 ident: bib14 article-title: Allocation of patients to treatment groups in a controlled clinical study publication-title: Br J Cancer – volume: 390 start-page: 1048 year: 2017 end-page: 1060 ident: bib22 article-title: Partial breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial publication-title: Lancet – volume: 27 start-page: 465 year: 2015 end-page: 471 ident: bib6 article-title: Examining determinants of radiotherapy access: do cost and radiotherapy inconvenience affect uptake of breast-conserving treatment for early breast cancer? publication-title: Clin Oncol – volume: 347 start-page: 1233 year: 2002 end-page: 1241 ident: bib1 article-title: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer publication-title: N Engl J Med – volume: 172 start-page: 201 year: 2018 end-page: 208 ident: bib5 article-title: Impact of race, ethnicity, and socioeconomic factors on receipt of radiation after breast conservation surgery: analysis of the National Cancer Database publication-title: Breast Cancer Res Treat – volume: 7 start-page: 73 year: 2017 end-page: 79 ident: bib15 article-title: Accelerated partial breast irradiation: executive summary for the update of an ASTRO Evidence-Based Consensus Statement publication-title: Pract Radiat Oncol – volume: 93 start-page: 1344 year: 2001 end-page: 1346 ident: bib3 article-title: Relationship of distance from a radiotherapy facility and initial breast cancer treatment publication-title: J Natl Cancer Inst – reference: Whelan T, Julian J, Levine M, et al. RAPID: a randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiation therapy (3D-CRT). San Antonio Breast Cancer Symposium; San Antonio, TX: Dec 4–8, 2018 (abstr GS4–03). – volume: 31 start-page: 2382 year: 2013 end-page: 2387 ident: bib10 article-title: Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343 publication-title: J Clin Oncol – volume: 265 start-page: 391 year: 1991 end-page: 395 ident: bib16 article-title: Treatment of early-stage breast cancer publication-title: JAMA – volume: 17 start-page: 1158 year: 2016 end-page: 1170 ident: bib17 article-title: 10-year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study publication-title: Lancet Oncol – volume: 387 start-page: 229 year: 2016 end-page: 238 ident: bib20 article-title: 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial publication-title: Lancet – volume: 347 start-page: 1233 year: 2002 ident: 10.1016/S0140-6736(19)32514-0_bib1 article-title: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa022152 – volume: 93 start-page: 1344 year: 2001 ident: 10.1016/S0140-6736(19)32514-0_bib3 article-title: Relationship of distance from a radiotherapy facility and initial breast cancer treatment publication-title: J Natl Cancer Inst doi: 10.1093/jnci/93.17.1344 – volume: 8 start-page: 161 year: 1992 ident: 10.1016/S0140-6736(19)32514-0_bib13 article-title: Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation: pathological findings from NSABP protocol B-06 publication-title: Semin Surg Oncol – volume: 31 start-page: 2382 year: 2013 ident: 10.1016/S0140-6736(19)32514-0_bib10 article-title: Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.45.2615 – ident: 10.1016/S0140-6736(19)32514-0_bib23 doi: 10.1158/1538-7445.SABCS18-GS4-04 – volume: 16 start-page: 266 year: 2015 ident: 10.1016/S0140-6736(19)32514-0_bib11 article-title: Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)71221-5 – volume: 67 start-page: 439 year: 2017 ident: 10.1016/S0140-6736(19)32514-0_bib18 article-title: Breast cancer statistics, 2017, racial disparity in mortality by state publication-title: CA Cancer J Clin – volume: 33 start-page: 37 year: 2018 ident: 10.1016/S0140-6736(19)32514-0_bib8 article-title: Breast cancer patients' preferences for adjuvant radiotherapy: whole breast irradiation vs partial breast irradiation—single institutional study publication-title: J Canc Educ doi: 10.1007/s13187-016-1016-3 – volume: 172 start-page: 201 year: 2018 ident: 10.1016/S0140-6736(19)32514-0_bib5 article-title: Impact of race, ethnicity, and socioeconomic factors on receipt of radiation after breast conservation surgery: analysis of the National Cancer Database publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-018-4881-0 – volume: 106 year: 2014 ident: 10.1016/S0140-6736(19)32514-0_bib4 article-title: Factors contributing to underuse of radiation among younger women with breast cancer publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djt340 – volume: 366 start-page: 2087 year: 2005 ident: 10.1016/S0140-6736(19)32514-0_bib2 article-title: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials publication-title: Lancet doi: 10.1016/S0140-6736(05)67887-7 – ident: 10.1016/S0140-6736(19)32514-0_bib19 doi: 10.1158/1538-7445.SABCS18-GS4-03 – volume: 387 start-page: 229 year: 2016 ident: 10.1016/S0140-6736(19)32514-0_bib20 publication-title: Lancet doi: 10.1016/S0140-6736(15)00471-7 – volume: 390 start-page: 1048 year: 2017 ident: 10.1016/S0140-6736(19)32514-0_bib22 article-title: Partial breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial publication-title: Lancet doi: 10.1016/S0140-6736(17)31145-5 – volume: 378 start-page: 1707 year: 2011 ident: 10.1016/S0140-6736(19)32514-0_bib12 article-title: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials publication-title: Lancet doi: 10.1016/S0140-6736(11)61629-2 – volume: 17 start-page: 1158 year: 2016 ident: 10.1016/S0140-6736(19)32514-0_bib17 article-title: 10-year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30067-5 – volume: 27 start-page: 465 year: 2015 ident: 10.1016/S0140-6736(19)32514-0_bib6 article-title: Examining determinants of radiotherapy access: do cost and radiotherapy inconvenience affect uptake of breast-conserving treatment for early breast cancer? publication-title: Clin Oncol doi: 10.1016/j.clon.2015.04.034 – volume: 265 start-page: 391 year: 1991 ident: 10.1016/S0140-6736(19)32514-0_bib16 article-title: Treatment of early-stage breast cancer publication-title: JAMA doi: 10.1001/jama.1991.03460030097037 – volume: 23 start-page: 273 year: 2014 ident: 10.1016/S0140-6736(19)32514-0_bib9 article-title: Influences on decision for mastectomy in patients eligible for breast conserving surgery publication-title: Breast doi: 10.1016/j.breast.2013.12.009 – volume: 37 start-page: 849 year: 1978 ident: 10.1016/S0140-6736(19)32514-0_bib14 article-title: Allocation of patients to treatment groups in a controlled clinical study publication-title: Br J Cancer doi: 10.1038/bjc.1978.124 – volume: 51 start-page: 451 year: 2015 ident: 10.1016/S0140-6736(19)32514-0_bib21 article-title: Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial publication-title: Eur J Cancer doi: 10.1016/j.ejca.2014.12.013 – volume: 82 start-page: 674 year: 2012 ident: 10.1016/S0140-6736(19)32514-0_bib7 article-title: Patient preferences and physician practice patterns regarding breast radiotherapy publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2010.11.077 – volume: 7 start-page: 73 year: 2017 ident: 10.1016/S0140-6736(19)32514-0_bib15 article-title: Accelerated partial breast irradiation: executive summary for the update of an ASTRO Evidence-Based Consensus Statement publication-title: Pract Radiat Oncol doi: 10.1016/j.prro.2016.09.007 – reference: 31900442 - Nat Rev Clin Oncol. 2020 Mar;17(3):134 – reference: 33220220 - Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1123-1128 – reference: 31813634 - Lancet. 2019 Dec 14;394(10215):2127-2129 |
| SSID | ssj0004605 |
| Score | 2.6997795 |
| Snippet | Whole-breast irradiation after breast-conserving surgery for patients with early-stage breast cancer decreases ipsilateral breast-tumour recurrence (IBTR),... Summary Background Whole-breast irradiation after breast-conserving surgery for patients with early-stage breast cancer decreases ipsilateral breast-tumour... |
| SourceID | unpaywall pubmedcentral proquest gale pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2155 |
| SubjectTerms | Adult Aged Algorithms Analysis Biopsy Brachytherapy Brachytherapy - methods Bream Breast cancer Breast Neoplasms - pathology Breast Neoplasms - radiotherapy Breast Neoplasms - surgery Cancer therapies Chemotherapy Combined Modality Therapy Equivalence Federal agencies Female Hispanic Americans Humans Incidence Irradiation Lumpectomy Lymphatic Metastasis Lymphatic system Mammography Mastectomy Mastectomy, Segmental Menopause Metastases Metastasis Middle Aged Neoplasm Grading Neoplasm Invasiveness Neoplasm Staging Patients Prognosis Radiation therapy Radioisotope brachytherapy Radiotherapy Dosage Randomization Sensitivity analysis Statistical models Subgroups Surgery Survival Survival Rate Toxicity Tumors |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3bbtQwELXKVgJeKu6kFDASDyDVbC6O10FCqKBWFaIrBFTqm-Vbtiutku1mI8Q38ZPMZJP0wkJ5je1E9ozPjOOZM4S8TDPvDQibec8945mXTGbWsVxbI4x0OgwxUfhoLA6P-aeT9GSDjLtcGAyr7DCxAWpXWvxHPgTLj0zugKfv52cMq0bh7WpXQkO3pRXcu4Zi7AbZjJEZa0A2P-yPv3xdlynZBL2f5_QMv_UPX0XZa_haxFn4N2t1Fb4v2K-rsZW36mKuf_7Qs9kFw3Vwh2y1HifdW6nIXbLhi3vk5lF7p36f_PpcFhOGCE3nK-oJCkfwerasaJlTmDIYJuSTcHSOagavMhjIvqTTxQKJDVCytCk13jYwixHaC_xTQatV1jUF15h65FJm4I1OfPcKizq3eEs1BZPpStA573bp_BRMK012qT-rp7ATEHxoU17kATk-2P_-8ZC1JRyYTWW4ZCmy08fSCxPaJPIS4MSBCI2MkkjbKLQ8NuBUQh9rbAxYwEUunDVwiJNecp48JIOiLPxjQhOec2lCneQxUgI58OxGxjjpnbYi0XFAeCcqZVt-cyyzMVNrAtmiTDUSVmFA3vTD2lW-boDo9EB12auAtwpM0HUDZT-wdW9Wbsv_DH2OCqeQsKPAiKCJrqtKqT0RSp4JmaUB2el0UbUoVKnzPROQF30zyBIvhXThy7rpE0s416ZJQB6tVLdfB8D7KBGJCMjoklL3HZCb_HJLMT1tOMpHyDkdy4AMe_X_Y3mrdVPd_vdEnpDb4LI2FTwivkMGy0Xtn4JbuDTP2r3-G8K-XC4 priority: 102 providerName: ProQuest |
| Title | Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0140673619325140 https://dx.doi.org/10.1016/S0140-6736(19)32514-0 https://www.ncbi.nlm.nih.gov/pubmed/31813636 https://www.proquest.com/docview/2325265012 https://www.proquest.com/docview/2322808653 https://pubmed.ncbi.nlm.nih.gov/PMC7199428 https://www.ncbi.nlm.nih.gov/pmc/articles/7199428 |
| UnpaywallVersion | submittedVersion |
| Volume | 394 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1474-547X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004605 issn: 1474-547X databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier Science Direct Freedom Collection customDbUrl: eissn: 1474-547X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004605 issn: 1474-547X databaseCode: ACRLP dateStart: 19950107 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1474-547X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0004605 issn: 1474-547X databaseCode: AKRWK dateStart: 19930102 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-547X dateEnd: 20250802 omitProxy: true ssIdentifier: ssj0004605 issn: 1474-547X databaseCode: 7X7 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest - Public Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250802 omitProxy: true ssIdentifier: ssj0004605 issn: 1474-547X databaseCode: 8C1 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1474-547X dateEnd: 20250802 omitProxy: true ssIdentifier: ssj0004605 issn: 1474-547X databaseCode: BENPR dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED9trQS88D0IjGIkHkCa23w4icNbmTZNjFVTRUV5imzH7Sq6tDSJEPxL_JOc0yRsZWjsJXmwz5Lt8905-d3vAF77kdYSN5tqzTRlkeaURyqhE6FkIHkibNskCp8MgqMR-zD2x1vg1LkwJWhfyVk3nZ9309lZia1cnqtejRPrhYbN1uXb0A58DL9b0B4NTvtfaqiiwSmVGUUhoz4Lx3-ydnpZ0-GNE7310LMzav_LH20a6AseahM9ebtIl-LHdzGfX3BNh_dgWE9qjUj52i1y2VU_N_gebzTr-3C3ClRJf930ALZ0-hBunVS_4h_Br4-LdEqNYSfLNWMFwZt7Mc8zspgQoRT6M0NDkZClGR6Hkgb_npPZamX4EIxCkLJCedVAlQF2r8wHDpKtk7UJRtREGwpmikHsVNdDKKOqq3dEEPS0yQJVVSd7ZHmGHpl4e0R_K2Z4gIzNImVVkscwOjz4tH9Eq8oPVPnczqlvSO1drgNpK8_RHK1Qgp5UcsdzhHJsxVyJsSj2UVK5aEJYMAkSJfHuxzVnzNuBVrpI9VMgHpswLm3hTVzDJJRgQBhKmXCdCBV4wrWA1fsfq4oW3VTnmMdX4N-cKC7VJrYt6DZi1SpfJxDUyhXXSa9opmP0XNcJ8kawiorW0c7_iL40Whwbno_UAImmosiyOO4HNmdRwCPfgt1awePKeGUxBtmmaAIuuAWvmmbcS_MvSaR6UZR9XI7XYd-z4Mn6PDTrgG7C8QIvsCC8dFKaDobS_HIL6nxJbV6puQW95kz9tbzZVVN9dmOJ53AHg9-yFojDdqGVrwr9AgPMXHZgOxyH-OT7Tgfa_ePh52N8vz8YnA47lbn5DWl9ePc |
| linkProvider | Unpaywall |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwELZKkSgviJtAoUYCCaSazeFkHSSEqkK1pbt9oZX6ZmzH2a60Srabjar-JiR-IzO5erBQXvoaH5I9n2fG8cw3hLwJY2s1CJtZyy3jsRVMxCZhqTI60iJRrouJwqP9aHDIvx2FRyvkV5sLg2GVrU6sFHWSG_xH3gPLj0zuoE8_z04YVo3C19W2hEYNiz17dgpXtuLT7heQ71vf3_l6sD1gTVUBZkLhLliIhOm-sJF2TeBZAQhPYFYtvMBTxnMN9zX4OdDHaOMDPHmURonRcK8QVnAewLy3yG0e-H1UBGLbW5aHWYXUn2cM9b53H9958XtYi8eZ-zdbeNU4XLCOVyM318psps5O1XR6wSzu3Cf3Gn-WbtUAfEBWbPaQ3Bk1L_aPyM9hno0Z6n86q4ktKFzwy-mioHlKlTFg9pCtIqEzBDFMpTFMfkEn8znSJiBuaFXIvGlgBuO_5_gfhBZ1TjcFx5taZGpm4OuObTuFQUTPP1JFwSAnOSDaJpt0dgyGmwab1J6UEzhnqNpoVbzkMTm8EVE-IatZntlnhAY85UK7Kkh9JBxKwG_sa50ImygTBcp3CG9FJU3Dno5FPKZySZicF8tKwtJ1yIduWLPL1w2IWhzINjcWtLkEA3fdQNENbJyn2in6n6EbCDiJdCAZxhuNVVkUUm5FruBxJOLQIestFmWj4wp5fiId8rprBlnik5PKbF5WfXwBt-YwcMjTGrrdPoA18YIoiBzSvwTqrgMyn19uySbHFQN6HxmtfeGQXgf_P7a3WLbU5_9eyAZZGxyMhnK4u7_3gtwF57iqFeLxdbK6mJf2JTigC_2qOvWU_LhpNfMb56SPlQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtQwELVKkQoviDuBQo0EEkg1m8RO4iAhVFGqll6EBJX2LdiOs11plWw3G1X9Jv6Ar2Mmt15YKC99XV9W9hzPjOOZM4S8CmJrNQibWSssE7GVTMYmZZkyOtQyVa6LicL7B-H2ofgyDIZL5FeXC4NhlZ1OrBV1Whj8Rj4Ay49M7qBPB1kbFvF1c-vj9JhhBSl8ae3KaTQQ2bWnJ3B9Kz_sbIKsX_v-1ufvn7ZZW2GAmUC6cxYgebovbahdwz0rAe0p_IOWHveU8VwjfA0-D_Qx2vgAVRFmYWo03DGklUJwmPcGuRlxHmM4YTSMFuVk1uH1Z9lDg2_9j2-8-C2syxPM_ZtdvGwozlnKy1Gct6p8qk5P1GRyzkRu3SV3Wt-WbjRgvEeWbH6frOy3r_cPyM-9Ih8xtAV02pBcULjsV5N5SYuMKmPABCJzRUqnCGiYSmPI_JyOZzOkUEAM0bqoedvADMaCz_CbCC2b_G4KTji1yNrMwO8d2W4Kg-ievaeKgnFOC0C3Tdfp9AiMOOXr1B5XYzhzqOZoXcjkITm8FlE-Ist5kdsnhHKRCaldxTMfyYdS8CEjrVNpU2VCrnyHiE5UiWmZ1LGgxyRZEDLnxUkt4cR1yLt-WLvLVw0IOxwkXZ4saPYEjN1VA2U_sHWkGgfpf4auIeASpAbJ8ZCNVFWWSbIRulLEoYwDh6x2WExafVcmZ6fTIS_7ZpAlPj-p3BZV3ceXcIMOuEMeN9Dt9wEsi8dDHjokugDqvgOyoF9sycdHNRt6hOzWvnTIoIf_H9tbLlrq038vZI2sgIJJ9nYOdp-R2-An12VDPLFKluezyj4HX3SuX9SHnpIf161lfgPBTZQE |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3bbhMxELVKKgEv5VpYKGAkHkCqk714HS9vEaKqEK0QIlJ4smyvk0akmzS7KwS_xE8yszfaUFT67ItkezxzvHvmDCGv4sQ5A4fNnOOO8cRJJhObsqm2RhiZat_HROGjY3E45h8m8WSLBG0uTEXat2bezxan_Wx-UnErV6d20PLEBkNUsw3lDbItYoDfPbI9Pv40-tpSFZGnVGUUDTmL-XDyJ2tnkHcdXgfJmwgiO2f-v-LRpoM-F6E22ZO3ymylf3zXi8W50HRwh3xuF1UzUr71y8L07c8Nvcdrrfou2WmAKh3VTffIlsvuk5tHza_4B-TXx2U2Y-jY6apWrKDwci8XRU6XU6qthXiGMhQpXeH0MJVB_ntB5-s16iGgQdCqQnnTwCwSu9f4gYPmdbI2BURNHUowMwCxM9dOYdFU12-pphBp0yWYqkv36eoEIjKN9qk7K-dwgdBn0aoqyUMyPnj_5d0hayo_MBtLv2AxitqH0gnj2yhwErxQCpHUyCAKtA18y0MDWBT6WGNDcCFcTEVqDbz9pJOcR7ukly0z95jQiE-5NL6OpiEqCaUACIfGpNKl2opIhx7h7fkr28iiY3WOhbqE_xYkqjIb5Xuk3w1rdvmqAaI1LtUmvYKbVhC5rhoou4ENKqrRzv8MfYFWrFDnI0Mi0UyXea7USPiSJ0ImsUf2WgNXjfPKFYBsLJoAG-6Rl10znCX-S9KZW5ZVn1DCcziOPPKovg_dPkCYCCIRCY8ML9yUrgNKml9sAZuvpM0bM_fIoLtTf21vftlSn1x7xFNyG8BvVQsk4HukV6xL9wwAZmGeNy7lN4LndAY |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-term+primary+results+of+accelerated+partial+breast+irradiation+after+breast-conserving+surgery+for+early-stage+breast+cancer%3A+a+randomised%2C+phase+3%2C+equivalence+trial&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Vicini%2C+Frank+A&rft.au=Cecchini%2C+Reena+S&rft.au=White%2C+Julia+R&rft.au=Arthur%2C+Douglas+W&rft.date=2019-12-14&rft.pub=Elsevier+Ltd&rft.issn=0140-6736&rft.eissn=1474-547X&rft.volume=394&rft.issue=10215&rft.spage=2155&rft.epage=2164&rft_id=info:doi/10.1016%2FS0140-6736%2819%2932514-0&rft.externalDocID=S0140673619325140 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0140-6736&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0140-6736&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0140-6736&client=summon |